{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:49:34Z","timestamp":1781812174912,"version":"3.54.5"},"reference-count":107,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jare.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T18:26:48Z","timestamp":1469644008000},"page":"113-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Hepatitis C and kidney disease: A narrative review"],"prefix":"10.1016","volume":"8","author":[{"given":"Rashad S.","family":"Barsoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad A.","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha S.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/01.bor.0000198002.42826.c2","article-title":"Cryoglobulinemic vasculitis","volume":"18","author":"Ferri","year":"2006","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.jare.2016.07.004_b0010","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1208642","article-title":"Therapy for hepatitis C virus-related cryoglobulinemic vasculitis","volume":"369","author":"Dammacco","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2893.2003.00462.x","article-title":"Occult hepatitis C virus infection in type II mixed cryoglobulinaemia","volume":"10","author":"Casato","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2016.07.004_b0020","first-page":"502156","article-title":"Hepatitis C virus infection and mixed cryoglobulinemia","author":"Lauletta","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jare.2016.07.004_b0025","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/ndt\/gfm205","article-title":"Hepatitis C virus: from entry to renal injury\u2014facts and potentials","volume":"22","author":"Barsoum","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jare.2016.07.004_b0030","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1099\/vir.0.81056-0","article-title":"Structural proteins of hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells","volume":"86","author":"Balasubramanian","year":"2005","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jceh.2014.01.004","article-title":"Acute kidney dysfunction in patients with chronic hepatitis C virus infection: analysis of viral and non-viral factors","volume":"4","author":"Satapathy","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000355753","article-title":"Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review","volume":"38","author":"Fabrizi","year":"2013","journal-title":"Kidney Blood Press Res."},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM198401053100107","article-title":"Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides","volume":"310","author":"Averbuch","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2016.07.004_b0050","unstructured":"Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET). <http:\/\/www.hcvtarget.org\/> [accessed 15th Sep 2015]."},{"issue":"4","key":"10.1016\/j.jare.2016.07.004_b0055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/kel425","article-title":"Hepatitis C virus infection, cryoglobulinaemia, and beyond","volume":"46","author":"Sansonno","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jare.2016.07.004_b0065","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0272-6386(96)90156-0","article-title":"High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin: a mechanism for induction of in situ immune complex glomerulonephritis?","volume":"27","author":"Fornasieri","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0070","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1111\/j.1523-1755.2004.66042.x","article-title":"The changing face of schistosomal glomerulopathy","volume":"66","author":"Baroum","year":"2004","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.jare.2016.07.004_b0075","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/ndt\/gfp167","article-title":"Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis","volume":"24","author":"Cao","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ndt\/17.2.239","article-title":"A comprehensive study of the association between hepatitis C virus and glomerulopathy","volume":"17","author":"Sabry","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0085","first-page":"71","article-title":"Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis","volume":"45","author":"Okada","year":"1996","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/ki.2014.181","article-title":"Novel evidence on hepatitis C virus\u2013associated glomerular disease","volume":"86","author":"Fabrizi","year":"2014","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0095","first-page":"109","article-title":"Systemic vasculitis in patients with hepatitis C","volume":"28","author":"Cacoub","year":"2001","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C infection and chronic renal diseases","volume":"4","author":"Perico","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.jare.2016.07.004_b0105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/archinte.167.12.1271","article-title":"Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease","volume":"167","author":"Tsui","year":"2007","journal-title":"Arch Int Med"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/ndt\/14.1.40","article-title":"Hepatitis virus infection in haemodialysis patients from Moldavia","volume":"14","author":"Covic","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.jare.2016.07.004_b0115","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/16.8.1669","article-title":"Risk of death and liver cirrhosis in anti-HCV +ve long-term haemodialysis patients","volume":"16","author":"Espinosa","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: Hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0125","first-page":"79","article-title":"Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit","volume":"102","author":"Yang","year":"2003","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jare.2016.07.004_b0130","unstructured":"World Health Organization. Hepatitis C. <http:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/index4.html> [last accessed 30th March 2016]."},{"issue":"5079","key":"10.1016\/j.jare.2016.07.004_b0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1126\/science.1279801","article-title":"Lack of protective immunity against reinfection with hepatitis C virus","volume":"258","author":"Farci","year":"1992","journal-title":"Science"},{"issue":"8894","key":"10.1016\/j.jare.2016.07.004_b0140","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0140-6736(94)91224-6","article-title":"Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children","volume":"343","author":"Lai","year":"1994","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of Hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2016.07.004_b0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2334-13-61","article-title":"Analysis of HCV quasispecies dynamic under selective pressure of combined therapy","volume":"13","author":"Jardim","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jare.2016.07.004_b0155","first-page":"51","article-title":"Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS\/UNOS database","author":"Bucci","year":"2004","journal-title":"Clin Transpl"},{"issue":"7","key":"10.1016\/j.jare.2016.07.004_b0160","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.transproceed.2010.04.056","article-title":"Kidney grafts from HCV +ve donors: advantages and disadvantages","volume":"42","author":"Maluf","year":"2010","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0165","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1399-0012.2011.01583.x","article-title":"The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience","volume":"26","author":"Singh","year":"2012","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/MNH.0b013e32834bba37","article-title":"Should we be using kidneys from hepatitis C virus-infected donors?","volume":"20","author":"Dom\u00ednguez-Gil","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jare.2016.07.004_b0175","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, evaluation and treatment of hepatitis C in chronic kidney disease","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2008","journal-title":"Kidney Int Suppl"},{"issue":"11","key":"10.1016\/j.jare.2016.07.004_b0180","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1681\/ASN.V7112469","article-title":"Hepatitis C virus- associated membranoproliferative glomerulonephritis in renal allografts","volume":"7","author":"Cruzado","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0185","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","article-title":"Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group","volume":"53","author":"Pereira","year":"1998","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.jare.2016.07.004_b0190","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/00007890-199610270-00004","article-title":"The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients","volume":"62","author":"Cosio","year":"1996","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0195","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1681\/ASN.V101146","article-title":"Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients","volume":"10","author":"Baid","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jare.2016.07.004_b0200","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1097\/01.ASN.0000145896.16153.43","article-title":"Hepatitis C, acute humoral rejection, and renal allograft survival","volume":"15","author":"Forman","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.jare.2016.07.004_b0205","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta- analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0210","article-title":"Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","volume":"63","author":"2013 USRDS Annual Data Report","year":"2014","journal-title":"Am J Kid Dis"},{"issue":"4","key":"10.1016\/j.jare.2016.07.004_b0215","first-page":"151","article-title":"Impact of hepatitis C virus infection in renal transplant recipients","volume":"24","author":"Narula","year":"2005","journal-title":"Indian J Gastroenterol"},{"issue":"Suppl_2","key":"10.1016\/j.jare.2016.07.004_b0220","first-page":"ii41","article-title":"Renal transplantation in patients with hepatitis C virus antibody. A long national experience","volume":"3","author":"Morales","year":"2010","journal-title":"NDT Plus"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0225","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/TP.0b013e318225dbae","volume":"92","author":"L\u00f3pez-Medrano","year":"2011","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0230","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.26.2007.S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"26","author":"Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"2003","journal-title":"Diabetes Care"},{"issue":"10 Suppl","key":"10.1016\/j.jare.2016.07.004_b0235","first-page":"SS3","article-title":"International expert panel. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0240","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0245","doi-asserted-by":"crossref","first-page":"E170","DOI":"10.1111\/j.1399-0012.2010.01247.x","article-title":"Risk factors and consequences of post-transplant diabetes mellitus","volume":"24","author":"Demirci","year":"2010","journal-title":"Clin Transplant"},{"issue":"12","key":"10.1016\/j.jare.2016.07.004_b0250","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/j.1600-6143.2009.02843.x","article-title":"Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients","volume":"9","author":"Baid-Agrawal","year":"2009","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.jare.2016.07.004_b0255","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2337\/diacare.28.4.940","article-title":"Hepatitis C virus infection and human pancreatic \u03b2-Cell dysfunction","volume":"28","author":"Masini","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jare.2016.07.004_b0260","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Moulin B;French PTLD Working Group. Post- transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-2277.2006.00416.x","article-title":"Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation","volume":"20","author":"Bakker","year":"2007","journal-title":"Transpl Int"},{"issue":"44","key":"10.1016\/j.jare.2016.07.004_b0270","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.3748\/wjg.v19.i44.7889","article-title":"Direct effect of hepatitis C virus on the lymphoid cells","volume":"19","author":"Kondo","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.jare.2016.07.004_b0275","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/ijc.26283","article-title":"DANVIR cohort study. Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study","volume":"130","author":"Omland","year":"2012","journal-title":"Int J Cancer"},{"issue":"19","key":"10.1016\/j.jare.2016.07.004_b0280","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2169\/internalmedicine.51.8404","article-title":"Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection","volume":"51","author":"Takahashi","year":"2012","journal-title":"Intern Med"},{"issue":"13","key":"10.1016\/j.jare.2016.07.004_b0285","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2007-07-101956","article-title":"Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients","volume":"110","author":"Morton","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jare.2016.07.004_b0290","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.meg.0000231752.50587.ae","article-title":"Occurrence of post- transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?","volume":"18","author":"Burra","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jare.2016.07.004_b0295","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11255-006-0050-1","article-title":"Hepatitis C virus related lymphoproliferative disorder in a renal transplant recipient","volume":"38","author":"Aravindan","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jare.2016.07.004_b0300","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00007890-199803150-00024","article-title":"Pre- transplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation","volume":"65","author":"Hestin","year":"1998","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0305","first-page":"88","article-title":"Proteinuria after kidney transplantation: its relation to hepatitis C virus and graft outcome","volume":"1","author":"Sabry","year":"2007","journal-title":"Iran J Kidney Dis"},{"issue":"10","key":"10.1016\/j.jare.2016.07.004_b0310","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/ndt\/14.10.2455","article-title":"Impaired kidney transplant survival in patients with antibodies to hepatitis C virus","volume":"14","author":"Gentil","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0315","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000188914","article-title":"Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C","volume":"72","author":"Brunkhorst","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.jare.2016.07.004_b0320","series-title":"The Kidney","first-page":"2625","article-title":"Clinical aspects of renal transplantation","author":"McKay","year":"1996"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0325","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-6143.2001.10212.x","article-title":"Hepatitis C virus infection and de novo glomerular lesions in renal allografts","volume":"1","author":"Cruzado","year":"2001","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0330","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.transproceed.2005.12.109","article-title":"De novo glomerulonephritis in renal allografts with hepatitis C virus infection","volume":"38","author":"Ozdemir","year":"2006","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1016\/j.jare.2016.07.004_b0335","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2215\/CJN.12571213","article-title":"De novo glomerular diseases after renal transplantation","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 8","key":"10.1016\/j.jare.2016.07.004_b0340","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/15.suppl_8.28","article-title":"Glomerular disease associated with hepatitis C virus infection in native kidneys","volume":"15","author":"Pouteil-Noble","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.jare.2016.07.004_b0345","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/00007890-199506270-00006","article-title":"De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients","volume":"59","author":"Roth","year":"1995","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0350","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1155\/2006\/301232","article-title":"Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation","volume":"20","author":"Zeman","year":"2006","journal-title":"Can J Gastroenterol"},{"issue":"10","key":"10.1016\/j.jare.2016.07.004_b0355","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/TP.0b013e31828a947b","article-title":"Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy","volume":"95","author":"Larsen","year":"2013","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.jare.2016.07.004_b0360","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/00007890-199706150-00017","article-title":"Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients","volume":"63","author":"Morales","year":"1997","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.565","article-title":"Hepatitis C virus infection in haemodialysis and kidney transplant patients","volume":"18","author":"Baid-Agrawal","year":"2008","journal-title":"Rev Med Virol"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0370","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ctr.12012","article-title":"Time of acquisition of HCV infection in renal transplant recipients: a major prognostic factor for disease progression","volume":"27","author":"Delladetsima","year":"2013","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0375","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.transproceed.2005.03.045","article-title":"Hepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients","volume":"37","author":"Melon","year":"2005","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0380","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1086\/315355","article-title":"Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients","volume":"181","author":"Izopet","year":"2000","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.jare.2016.07.004_b0385","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/TP.0b013e3181722f3a","article-title":"Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C","volume":"85","author":"Luan","year":"2008","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0390","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/jhep.2003.50278","article-title":"A model to predict severe HCV-related disease following liver transplantation","volume":"38","author":"Berenguer","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0395","doi-asserted-by":"crossref","first-page":"e9815","DOI":"10.1371\/journal.pone.0009815","article-title":"Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A","volume":"5","author":"Fernandes","year":"2010","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0400","first-page":"16","article-title":"Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation","volume":"75","author":"Kahraman","year":"2011","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0405","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1681\/ASN.V961109","article-title":"Fibrosingcholestatic hepatitis in hepatitis C virus-infected renal transplant recipients","volume":"9","author":"Munoz De Bustillo","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0410","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2893.2007.00907.x","article-title":"Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials","volume":"15","author":"Fabrizi","year":"2008","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jare.2016.07.004_b0415","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2007.11.003","article-title":"Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms","volume":"51","author":"Gordon","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0420","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among haemodialysis patients","volume":"35","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"issue":"S2","key":"10.1016\/j.jare.2016.07.004_b0425","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S0168-8278(15)30147-1","article-title":"Safety of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study","volume":"62","author":"Pockros","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2016.07.004_b0430","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end-stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"issue":"299","key":"10.1016\/j.jare.2016.07.004_b0435","first-page":"91","article-title":"Interferon: pharmacokinetics and toxicity","volume":"299","author":"Scott","year":"1982","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.jare.2016.07.004_b0440","unstructured":"University of Liverpool: Ribavirin PK fact sheet <http:\/\/www.hivdruginteractions.org\/data\/FactSheetImages\/FactSheet_DrugID_112.pdf> [last accessed 16th October 2015]."},{"issue":"6","key":"10.1016\/j.jare.2016.07.004_b0445","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.transproceed.2009.06.140","article-title":"Results of hepatitis C virus treatment in patients on hemodialysis: data from published meta-analyses in 2008","volume":"41","author":"Casanovas Taltavull","year":"2009","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0450","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10067-005-1093-x","article-title":"Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature","volume":"24","author":"Beuthien","year":"2005","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0455","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1159\/000189444","article-title":"Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C","volume":"74","author":"Rostaing","year":"1996","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0460","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jare.2016.02.006","article-title":"Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations \u2013 an Egyptian perspective","volume":"7","author":"El-Fishawy","year":"2016","journal-title":"J Adv Res"},{"key":"10.1016\/j.jare.2016.07.004_b0465","unstructured":"CATIE: Treatment update 198. The changing role of SVR12 in clinical trials of HCV drugs <http:\/\/www.catie.ca\/en\/treatmentupdate\/treatmentupdate-198\/hepatitis-c-virus\/changing-role-svr12-clinical-trials-hcv-d> [accessed 16 March 2016]."},{"issue":"S2","key":"10.1016\/j.jare.2016.07.004_b0470","doi-asserted-by":"crossref","first-page":"S619","DOI":"10.1016\/S0168-8278(15)30975-2","article-title":"Daclatasvir Plus Sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program","volume":"62","author":"Welzel","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2016.07.004_b0475","unstructured":"FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. <http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm468634.htm> [accessed 16 March 2016]."},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0480","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jare.2016.07.004_b0485","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"For the ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jare.2016.07.004_b0490","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0495","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2893.1995.tb00070.x","article-title":"Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment","volume":"2","author":"Weltman","year":"1995","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0500","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.jare.2016.07.004_b0505","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"(EASL) Recommendations on Treatment of Hepatitis C 2015","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2016.07.004_b0510","unstructured":"Full prescribing information for HARVONI. FDA-approved patient labeling Issued: March 2015. Last reviewed on RxList: 4\/7\/2015. Reference ID: 3642283. U.S. <www.gilead.com>."},{"issue":"3","key":"10.1016\/j.jare.2016.07.004_b0515","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3851\/IMP2985","article-title":"COMMAND-4 study team. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4)","volume":"21","author":"H\u00e9zode","year":"2015","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.jare.2016.07.004_b0520","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP2941","article-title":"Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment","volume":"20","author":"Garimella","year":"2015","journal-title":"Antivir Ther"},{"issue":"10003","key":"10.1016\/j.jare.2016.07.004_b0525","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jare.2016.07.004_b0530","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"9986","key":"10.1016\/j.jare.2016.07.004_b0535","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"H\u00e9zode","year":"2015","journal-title":"Lancet"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123216300522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123216300522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:43:28Z","timestamp":1761857008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123216300522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2090123216300522"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2016.07.004","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C and kidney disease: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}